Last year, Eli Lilly bought Boston-based biotech Versanis in a deal worth $1.9bn to get its hands on its muscle-preserving treatment to complement its weight-loss drugs. BioAge, a biotech with a ...
BioAge Labs (NASDAQ: BIOA) is a biotech company that you may be hearing a lot about over the coming years. Dedicated to developing medicines for closely linked problems like metabolic disorders and ...
And what better place to find dominant companies with decades-long growth opportunities than in healthcare? Healthcare isn't ...